| Customization: | Available |
|---|---|
| CAS No.: | 302962-49-8 |
| Formula: | C22h26cln7o2s |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
| Product name | Dasatinib |
| Appearance | White powder |
| Cas number | 302962-49-8 |
| MF | C22H26ClN7O2S |
| MW | 488.007 |
Dasatinib/Sprycel is indicated for adult patients with chronic myelogenous leukemia who have been treated, including Imatinib mesylate/Gleevec, resistant or intolerant to all stages of disease (chronic, accelerated, lymphocytic, and myeloid rapid change). The FDA also approved dasatinib for the treatment of adults with Philadelphia chromosom-positive acute lymphoblastic leukemia who are resistant or intolerant to other therapies.
Dasatinib, a polytyrosine kinase inhibitor, was approved for both indications based on safety and efficacy results and other supporting data from four international, multicenter Phase II trials involving a total of 911 patients. The most commonly reported side effects in clinical studies include fluid retention, gastrointestinal symptoms and bleeding events. The most commonly reported serious side effects are fever, pleural effusion, febrile neutral white) for myelogenous leukemia (CML).
){kind=link}